‘No vascular protective effect’ of HCQ in patients with SLE
medwireNews: Long-term hydroxychloroquine (HCQ) therapy is not associated with a reduced risk for vascular events among patients with systemic lupus erythematosus (SLE), Taiwanese researchers report.
In a database study, Tien-Hsing Chen (Chang Gung University College of Medicine, Keelung) and co-authors found that 7.1% of 1946 HCQ-treated patients experienced an acute coronary syndrome, ischemic stroke, pulmonary embolism, or deep vein thrombosis over a mean follow-up of 7.4 years, compared with 7.7% of 1946 patients who were not treated with HCQ.
These findings translate into a comparable risk for vascular events between the two groups, with a hazard ratio of 0.91, and the results were consistent in subgroup analyses of different HCQ doses, report the researchers in Rheumatology.
Therefore, “[l]ong-term HCQ appears to have no vascular protective effect in patients with SLE,” write Chen and colleauges.
And they conclude that “[f]urther studies in other ethnic groups will be necessary to further validate the results of the present study.”
medwireNews is an independent medical news service provided by Springer Healthcare. © 2017 Springer Healthcare part of the Springer Nature group